| 1.37 -0.08 (-5.52%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.36 | 1-year : | 4.53 |
| Resists | First : | 2.87 | Second : | 3.88 |
| Pivot price | 1.88  |
|||
| Supports | First : | 1.25 | Second : | 1.04 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 2.2 |
| MA(100) : | 4.05 |
MA(250) : | 19.36 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 6.6 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 97.5 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MEDS ] has closed above bottom band by 31.1%. Bollinger Bands are 2.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
Tue, 18 Aug 2026
DataMeds AI reports Q2 2026 revenue $1.78M, net loss $18.36M; app launch expected Sept 2026 - TradingView
Tue, 18 Aug 2026
Form 8K DataMeds AI Inc For: 18 August By Investing.com - Investing.com Canada
Tue, 18 Aug 2026
DataMeds AI (NASDAQ: MEDS) faces $19.5M deficit, 1-for-50 reverse split - Stock Titan
Tue, 18 Aug 2026
DataMEDS AI (MEDS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Mon, 17 Aug 2026
DataMeds AI's $6.5M Funding Precedes a Planned App Launch - Stock Titan
Mon, 17 Aug 2026
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 60.3 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 105 (K) |
| Shares Short P.Month | 445 (K) |
| EPS | -44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.33 |
| Profit Margin | 0 % |
| Operating Margin | -385.8 % |
| Return on Assets (ttm) | -79.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -85.6 % |
| Gross Profit (p.s.) | -2.44 |
| Sales Per Share | 4.92 |
| EBITDA (p.s.) | -18.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.22 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -0.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|